Clay Siegal is the founder and the CEO of Seattle Genetics. Clay Siegal has a Ph.D. in Genetics, George Washington University, and B.S in Zoology, University of Maryland. Seattle Genetics is studying, manipulating, and packaging drugs. They also deal with human antibodies. This company was founded in 1998, with great strength in antibodies and the therapies around that. These antibodies deliver toxic substances to the cancer cells as well as destroy them. This company has over 900 employees and ranks highest in biotechnology, Washington. It invests in marketing and research in the industry. Clay Siegal says that the company is an emerging globally, multiproduct, and an oncology company. Clay Siegal points out several drugs showing his desire for building the company. He is ambitious to moving from biotechnology into a firm for extensive drug development in dealing with complex matters. Clay Siegal intends to help the company grow into great international marketing for new drugs.
The company Clay Siegal leads, Seattle Genetics, is already growing and making a mark in the market. This growth is identified through the sales of about $418 million in 2016, and it is still making success in the recent years. Their focus is the antibody-drug conjugate that targets antigens. The drug attaches to the external parts of the cancer cells in Hodgkin lymphoma and other diseases, so that it produces a toxin that kills them. The analogy is called smart bombs.
Clay Siegal is a scientist trained and has a great emphasis on cancer therapies, research, scientific innovations, and drug development. He has a passion for helping patients. In his leadership, Clay Siegal has led the company in developing the antibody-drug conjugates. He has also led the company to collaborate with Takeda Pharmaceutical Company to make ADCETRIS a global brand, which has been approved in over 65 countries. Clay Siegal has continued to lead the company, Seattle Genetics, into having multiple strategic licenses for the ADC technology. There has been many collaborations and programs towards this amazing technology. Through Clay Siegal leadership, the company has conducted capital generation programs, which has secured more than $1.2 billion. This has been through private and public financing options, which included the initial public offering 2001 in the company.
Before working with Seattle Genetics, Clay Siegal worked with Bristol-Myers Squibb Pharmaceutical Research Institute between 1991 and 1997. Other institutes he has worked with are National Cancer Institute and National Institute of Health. Clay Siegal’s service is extended to Boards of Directors of Ultragenyx Pharmaceutical, Washington Roundtable, and BioPharmaceuticals. In addition to the medical knowledge, Clay Siegal is an author of over 70 publications. He has 15 patents.